Pressmeddelanden
PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, informs of its p...
PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
REG
MAR
PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors...
PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS - CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
Rapporter
Video
Finansiell kalender
Om PILA PHARMA
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs 2,17 SEK (2025-11-04)
Förändring −53,53% (2024-11-06)